XML 72 R57.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Deficit) (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Aug. 15, 2018
$ / shares
shares
Apr. 04, 2018
$ / shares
shares
Dec. 11, 2017
Oct. 22, 2018
USD ($)
$ / shares
shares
Oct. 19, 2018
Jul. 31, 2018
shares
Jun. 30, 2018
shares
Apr. 30, 2018
shares
Feb. 22, 2018
shares
Feb. 19, 2018
Jun. 23, 2017
Jun. 22, 2017
May 10, 2018
Jun. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Feb. 28, 2018
shares
Dec. 31, 2017
ILS (₪)
shares
Stockholders' Deficit (Textual)                                    
Future investment exercised | $                             $ 1,176      
Future investment exercised, shares       267,000                            
Company received amount of common stock | $                             $ 16      
Common stock, par value | $ / shares                             $ 0.001 $ 0.001    
Exercise of options into common stock | $                               $ 21    
Warrants remain outstanding                             788,658   788,658  
Aggregate exercise price of warrants | $                             $ 1,145      
Common stock shares issued                             8,957,550 4,350,608   4,350,608
Registration statement, description                         The Company filed an amendment to the S-1 Registration Statement, for the purpose of registering (i) 922,330 shares of Common Stock that were outstanding as of that date; and (ii) 338,945 shares of Common Stock which are issuable upon conversion of the 2016 Loan and/or the 2017 Loan. On July 12, 2018, the S-1 Registration Statement has been declared effective by the SEC.          
Common stock value issued for services | $                             $ 54      
Common stock shares issued for services                             55,000      
Restricted stock units, value | $                           $ 471        
Vest options exercisable, term                             2 years 6 months      
Unrecognized compensation cost | $                             $ 295      
Contractual term of stock-based grants, description                             The Company and five representative companies and expected term of stock-based grants of 7 years.      
Purchase agreement, description       The Company granted to the investors thereunder, for a period of three years from the closing date of the Purchase Agreement, a right of participation of up to an aggregate of 35% in any subsequent offering of the Company, subject to certain exceptions.                            
Warrant term, description       The Series A Warrants have a term of 5 years from issuance, and the Series B Warrants will have a term that expires 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) has occurred, the expiration date of the Series B Warrants will be extended by one day.                            
Trading activities, description       During the period commencing upon execution of the Purchase Agreement, and expiring on the trading day immediately following the date that the Company has raised, beginning after the issuance date of the Warrants, at least $10 million in gross proceeds from the issuance of the Company's securities, the Company issues or sells common stock (or securities convertible into or exercisable into common stock) at a purchase price (or conversion or exercise price, as applicable) lower than the exercise price of the Warrants, than the exercise price of the Warrants will be reduced to such lower price, subject to certain exceptions.                            
Exercise price of warrants | $ / shares       $ 1.00                            
Legal expenses | $       $ 50                            
Non-accountable expense allowance | $       $ 30                            
Maturity date, description         (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the Registration Rights Agreement covering the resale of all common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale for investors who are not a party to the Loan Agreements Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the Amendment, the expiration date of the investment right under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements Maturity Date.                          
Investor [Member]                                    
Stockholders' Deficit (Textual)                                    
Ownership, percentage       9.99%                            
Liquidated damages to investors, description       The Company shall pay to each investor cash equal to 2% of such investor's total purchase price on the dates of each deficiency and on the 30th day after such deficiencies until such deficiencies are cured, up to a maximum of 10% of the purchase price.                            
Beneficial Owner [Member]                                    
Stockholders' Deficit (Textual)                                    
Ownership, percentage       4.99%                            
Mesodi [Member]                                    
Stockholders' Deficit (Textual)                                    
Future investment exercised, shares       89                            
Fee amount | $       $ 89                            
Series A Preferred Stock [Member]                                    
Stockholders' Deficit (Textual)                                    
Common stock value issued for services | $                             $ 440      
Common stock shares issued for services                             440,000      
Purchase agreement, description       (i) 150 days following the date that all of the common stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Warrants, are registered for resale, (ii) six months after the date that a non-affiliate investor under the Purchase Agreement may first sell securities purchased thereunder under Rule 144, (iii) 120 days following the listing of the common stock on a Qualified Market (as defined below) and (iv) the first trading day that the weighted average price of the common stock exceeds $5.00 per share for 10 consecutive trading days.                            
Series A Certificate of Designations [Member]                                    
Stockholders' Deficit (Textual)                                    
Preferred stock, designated       1,350                            
Preferred stock stated value | $       $ 1,000                            
Shares of common stock, dividing | $       $ 1,000                            
Conversion price | $ / shares       $ 1.00                            
Converted instrument, shares       1,000                            
Series A Certificate of Designations [Member] | Investor [Member]                                    
Stockholders' Deficit (Textual)                                    
Ownership, percentage       9.99%                            
Series A Certificate of Designations [Member] | Beneficial Owner [Member]                                    
Stockholders' Deficit (Textual)                                    
Ownership, percentage       4.99%                            
Service Providers [Member]                                    
Stockholders' Deficit (Textual)                                    
Common stock value issued for services | $                             $ 381      
Common stock shares issued for services           67,778                        
Two Service Providers [Member]                                    
Stockholders' Deficit (Textual)                                    
Common stock value issued for services | $                             $ 126      
Common stock shares issued for services             24,306 24,306                    
2012 Plan [Member]                                    
Stockholders' Deficit (Textual)                                    
Granted term in excess                             10 years      
Reserved for issuance, common stock                             45,370      
Common stock, par value | $ / shares                             $ 0.001      
Common stock available for future grant                             40,474      
Common stock outstanding and exercisable                             4,896      
Restricted Stock Units (RSUs)                                    
Stockholders' Deficit (Textual)                                    
Number of options, granted                             131,200      
Officer [Member]                                    
Stockholders' Deficit (Textual)                                    
Common stock outstanding and exercisable   229,500                                
Registration statement, description   295                                
Common stock shares issued for services   131,200                                
Options outstanding and exercisable | $ / shares   $ 3.59                                
Vest options exercisable, term   36 months                                
Board of Directors [Member]                                    
Stockholders' Deficit (Textual)                                    
Reverse stock split, description     The Company announced a notice of special meeting of stockholders, according to which, a special meeting of the stockholders was held on February 19, 2018, for the purpose of considering to grant the Company's Board of Directors the authority, in its sole direction, to approve an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200.           The Company's Board of Directors approved a reverse stock split of the Company's issued and outstanding Common Stock by a ratio of 1-for-24 ("Reverse Stock Split"). The stockholders of the Company approved a reverse stock split of the Company's issued and outstanding Common Stock by a ratio of not less than 1-for-10 and not more than 1-for-200 at any time prior to February 19, 2019, with such ratio to be determined by the Company's Board of Directors, in its sole discretion.                
Common stock outstanding and exercisable   229,500                                
Registration statement, description   295                                
Common stock shares issued for services   131,200                                
Options outstanding and exercisable | $ / shares   $ 3.59                                
Vest options exercisable, term   36 months                                
Consultant [Member]                                    
Stockholders' Deficit (Textual)                                    
Common stock outstanding and exercisable 25,500 229,500                                
Registration statement, description   295                                
Common stock shares issued for services   131,200                                
Options outstanding and exercisable | $ / shares $ 4.50 $ 3.59                                
Vest options exercisable, term 36 months 36 months                                
2018 Plan [Member] | Board of Directors [Member]                                    
Stockholders' Deficit (Textual)                                    
Description of investments                 (i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.                  
Common stock shares issued                 2,500,000                  
2018 Plan [Member] | Directors, Officers and Consultant [Member]                                    
Stockholders' Deficit (Textual)                                    
Number of options, granted                             255,000      
2016 Investment Right [Member]                                    
Stockholders' Deficit (Textual)                                    
Future investment exercised | $                             $ 853      
Future investment exercised, shares                             217,442      
Shares of common stock, per share | $ / shares                             $ 1.308      
2017 Investment Right [Member]                                    
Stockholders' Deficit (Textual)                                    
Future investment exercised | $                             $ 853      
Future investment exercised, shares                             427,048      
Shares of common stock, per share | $ / shares                             $ 1.332      
Private Placement Agreement [Member]                                    
Stockholders' Deficit (Textual)                                    
Description of investments                     Pursuant to the 2017 PIPE Agreements, the 2017 PIPE Investors agreed to invest a total of NIS 3,490,000 (approximately $966) in exchange for a total of 860,987 ordinary shares of Wize Israel (the "2017 PIPE"), at a price per share of NIS 4.05 (approximately $1.15), with Peretz undertaking to invest NIS 490,000 (approximately $139 according to the exchange rate as of June 23, 2017) in exchange for the private placement of 120,884 ordinary shares of Wize Israel (the "Peretz Investment") and each of Zrachia, Sadan and Rubini (the "Other Investors") undertaking to invest NIS 1,000,000 (approximately $282 according to the exchange rate as of June 23, 2017) in exchange for the private placement of 246,701 ordinary shares of Wize Israel each (together, the "Other Investments"). Subject to the Closing Date of the Merger, Wize Israel also undertook to cause the Company to grant warrants to each of the 2017 PIPE Investors Warrants, with each Warrant being exercisable into one share of the Company's common stock, par value $0.001 per share (the "Common Stock"), with a term of three years from the date of grant.              
Private Placement Agreement [Member] | Series A Preferred Stock [Member]                                    
Stockholders' Deficit (Textual)                                    
Purchase agreement, description       (i) 3,100,000 shares of common stock, for a purchase price of $1.00 per share, and (ii) 1,350 shares of newly created Series A Preferred Stock (each convertible into 1,000 shares of common stock), for a purchase price of $1,000 per share, for aggregate gross proceeds under the Purchase Agreement of $4,450. The Company also issued to the investors Series A warrants (the "Series A Warrants") to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)), and Series B warrants (the "Series B Warrants, and together with the Series A Warrants, the "Warrants"), to purchase an aggregate of 4,450,000 shares of common stock (equal to 100% of the shares of common stock sold (on an as-converted basis with respect to shares of Series A Preferred Stock)). The Series A Warrants have an exercise price of $1.10 per share, and the Series B Warrants have an exercise price of $1.00 per share.                            
Warrants [Member]                                    
Stockholders' Deficit (Textual)                                    
Description of investments                     (i) 30,625 warrants to Peretz and (ii) 62,500 warrants to each of the Other Investors, each warrant exercisable into one ordinary share of Wize Israel, at an exercise price of NIS 28.8 per share (approximately $8.4 according to the exchange rate as of December 31, 2017). According to the Exchange Ratio, Peretz was granted 126,928 Warrants exercisable into Common Stock and each of the Other Investors was granted 259,036 Warrants exercisable into Common Stock. Sadan's commitment to provide his portion of the Other Financing was conditioned upon Wize Israel not raising more than NIS 3,500,000 (approximately $988 according to the exchange rate as of June 23, 2017) and not less than NIS 2,000,000 (approximately $565 according to the exchange rate as of June 23, 2017) in the 2017 PIPE, including the amount to be invested by Sadan.              
Issued shares of common stock                             144,168      
Warrants exercised shares of common stock                             144,168      
Warrants remain outstanding                             759,871      
Aggregate exercise price of warrants | $                             $ 292      
Peretz Investment and Other Investments [Member]                                    
Stockholders' Deficit (Textual)                                    
Future investment exercised                               $ 1,000   ₪ 3,490,000
Future investment exercised, shares                               860,987   860,987
Exchange rate, description                       The 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted from NIS 24.00 (approximately $6.72 according to the exchange rate as of June 23, 2017) to NIS 16.8 (approximately $4.8 according to the exchange rate as of June 23, 2017) and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15). As a result of the 2017 Loan Amendment (see note 8 above), the aggregate principal amount of the 2017 Loan is $822,144 and the 2017 Loan Conversion Price was adjusted to $1.1112.